Hemorrhage induced by antithrombotic agents: new insights from a real-world pharmacovigilance study

References

• Duffett L. Deep Venous Thrombosis. Ann Intern Med. 2022;175(9):ITC129–ITC144. doi: 10.7326/AITC202209200
   PubMed Web of Science ®Google Scholar
• Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: executive summary. A statement for healthcare professionals from the neurocritical care society and the society of critical care medicine. Crit Care Med. 2016;44(12):2251–2257. doi: 10.1097/CCM.0000000000002057
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Nice guideline (CG144). 2012.
   Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease CHEST guideline and expert panel report. Chest. 2016;149(2):315–352. doi: 10.1016/j.chest.2015.11.026
   PubMed Web of Science ®Google Scholar
• Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-Segment elevation the task force for the management of acute myocardial infarction in patients presenting with ST-Segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177.
   PubMed Web of Science ®Google Scholar
• Berge E, Whiteley W, Audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic Stroke. Eur Stroke J. 2021;6(1):I–LXII. doi: 10.1177/2396987321989865
   PubMed Web of Science ®Google Scholar
• Twine CP, Kakkos SK, Aboyans V, et al. Editor’s choice-European Society for Vascular Surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases. Eur J Vasc Endovascular Surg. 2023;65(5):627–689.
   PubMed Web of Science ®Google Scholar
• Schulman S, Beyth RJ, Kearon C, et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):257S–298S. doi: 10.1378/CHEST.08-0674
   PubMed Web of Science ®Google Scholar
• Lansberg MG, Albers GW, Wijman CAC. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007;24(1):1–10. doi: 10.1159/000103110
   PubMed Web of Science ®Google Scholar
• Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425–435. doi: 10.1182/BLOOD-2018-06-820746
   PubMed Web of Science ®Google Scholar
• Investigators, A. S. G., Investigators, E. S. G., Investigators, N. R.-P. S. G., Hacke W, Donnan G, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–774.
   PubMed Web of Science ®Google Scholar
• Lancaster TR. The impact of long-term warfarin therapy on quality of life: evidence from a randomized trial. Arch Intern Med. 1991;151(10):1944–1949. doi: 10.1001/ARCHINTE.1991.00400100032005
   PubMedGoogle Scholar
• de Germay S, Bagheri H, Despas F, et al. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology (Oxford). 2020;59(9):2360–2367. doi: 10.1093/RHEUMATOLOGY/KEZ604
   PubMed Web of Science ®Google Scholar
• Stricker BC, Psaty BM. Detection, verification, and quantification of adverse drug reactions. BMJ. 2004;329(7456):44–47. doi: 10.1136/BMJ.329.7456.44
   PubMedGoogle Scholar
• Kumazawa R, Jo T, Matsui H, et al. Direct oral anticoagulants versus warfarin for secondary prevention of cerebral Infarction and bleeding in older adults with atrial fibrillation. J Am Geriatr Soc. 2022;70(7):2029–2039. doi: 10.1111/JGS.17770
   PubMed Web of Science ®Google Scholar
• Pufulete M, Harris J, Pouwels K, et al. Real-world bleeding in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and prescribed different combinations of dual antiplatelet therapy (DAPT) in England: a population-based cohort study emulating a “target trial. Open Heart. 2022;9(2):e001999. doi: 10.1136/OPENHRT-2022-001999
   PubMed Web of Science ®Google Scholar
• Cornelius VR, Sauzet O, Evans SJW. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 2012;35(7):599–610. doi: 10.2165/11599740-000000000-00000
   PubMed Web of Science ®Google Scholar
• Mazhar F, Battini V, Gringeri M, et al. The impact of anti-TNFα agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database. Expert Opin Biol Ther. 2021;21(9):1281–1290.
   PubMed Web of Science ®Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HGM, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. doi: 10.1002/pds.668
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419–e496. doi: 10.1378/chest.11-2301
   Web of Science ®Google Scholar
• Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2):E669–E690.
   Web of Science ®Google Scholar
• Zhang FM, Yang B, Ly M, et al. Structural characterization of heparins from different commercial sources. Anal Bioanal Chem. 2011;401(9):2793–2803. doi: 10.1007/s00216-011-5367-7
   PubMed Web of Science ®Google Scholar
• Kamhi E, Joo EJ, Dordick JS, et al. Glycosaminoglycans in infectious disease. Biol Rev. 2013;88(4):928–943. doi: 10.1111/brv.12034
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330–1336. doi: 10.1056/NEJM199505183322003
   PubMed Web of Science ®Google Scholar
• Hirsh J, Levine MN. Low molecular weight heparin. Blood. 1992;79(1):1–17. doi: 10.1182/BLOOD.V79.1.1.1
   PubMed Web of Science ®Google Scholar
• Hao C, Sun MJ, Wang HM, et al. Low molecular weight heparins and their clinical applications. In: Zhang L, editor Glycans and glycosaminoglycans as clinical biomarkers and therapeutics, PT B. Vol. 163. 2019; p. 21–39. doi: 10.1016/bs.pmbts.2019.02.003
   Google Scholar
• Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25:5–16. (Meeting on Differentiation of Low Molecular Weight Heparins-Applied and Clinical Considerations).
   PubMed Web of Science ®Google Scholar
• Nicolau JC, Cohen M, Montalescot G. Differences among Low-Molecular-Weight Heparins: evidence in patients with acute coronary syndromes. J Cardiovasc Pharmacol. 2009;53(6):440–445. doi: 10.1097/FJC.0b013e3181a59abc
   PubMed Web of Science ®Google Scholar
• Torri G, Naggi A. Heparin centenary - an ever-young life-saving drug. Int J Cardiol. 2016;212:S1–S4. doi: 10.1016/S0167-5273(16)12001-7
   PubMed Web of Science ®Google Scholar
• Guerrini M, Bisio A. Low-Molecular-Weight Heparins: differential characterization/physical characterization. Handb Exp Pharmacol. 2012;207(207):127–157. doi: 10.1007/978-3-642-23056-1_7
   Google Scholar
• Merli GJ, Vanscoy GJ, Rihn TL, et al. Applying scientific criteria to therapeutic interchange: a balanced analysis of low-molecular-weight heparins. J Thromb Thrombolysis. 2001;11(3):247–259. doi: 10.1023/A:1011969005756
   PubMed Web of Science ®Google Scholar
• Fangting LI, Yongzhan WAN, Jiaxin ZENG, et al. Evaluation of clinical rationality of low molecular weight heparin drugs. Central South Pharm. 2021;19(2):326–330.
   Google Scholar
• Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510. doi: 10.1056/NEJMoa1007903
   PubMed Web of Science ®Google Scholar
• Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297. doi: 10.1056/NEJMoa1113572
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509–1524.
   PubMed Web of Science ®Google Scholar
• Mentias A, Saad M, Michael M, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair. J Am Heart Assoc. 2022;11(17). doi: 10.1161/JAHA.122.026666
   Web of Science ®Google Scholar
• Ou WC, He YC, Li AQ, et al. Genotype frequencies of CYP2C19, P2Y(12) and GPIIIa polymorphisms in coronary heart disease patients of han ethnicity, and their impact on clopidogrel responsiveness. Int Heart J. 2016;57(5):586–592. doi: 10.1536/ihj.16-006
   PubMed Web of Science ®Google Scholar
• Capodanno D, Alberts M, Angiolillo DJ. Antithrombotic therapy for secondary prevention of atherothrombotic events in cerebrovascular disease. Nat Rev Cardiol. 2016;13(10):609–622. doi: 10.1038/NRCARDIO.2016.111
   PubMed Web of Science ®Google Scholar
• Scalia L, Calderone D, Capodanno D. Antiplatelet therapy after noncardioembolic ischemic stroke or transient ischemic attack. Expert Rev Clin Pharmacol. 2022;15(9). doi: 10.1080/17512433.2022.2118713
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• STOPDAPT-2; Investigators, S.-2 A. C. S., Obayashi Y, Watanabe H, et al. Clopidogrel monotherapy after 1-month dual anti platelet therapy in percutaneous coronary intervention: from the STOPDAPT-2 total cohort. Circ Cardiovasc Inter. 2022;15(8). doi: 10.1161/CIRCINTERVENTIONS.122.012004
   Web of Science ®Google Scholar
• Council, A. H. A. S., Nursing, C. C., Dis, C. P. V., Cardiology, C. C., Jauch EC, Saver JL, et al. Guidelines for the early management of patients with acute ischemic stroke a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2013;44(3):870–947.
   PubMed Web of Science ®Google Scholar
• Study SEAAS, Hacke W, Kaste M, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998;352(9136):1245–1251.
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the safe implementation of thrombolysis in stroke-monitoring study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275–282.
   PubMed Web of Science ®Google Scholar
• Teekaput C, Thiankhaw K, Tanprawate S, et al. Outcomes of asymptomatic recombinant tissue plasminogen activator associated intracranial hemorrhage. PLoS One. 2022;17(8):e0272257. doi: 10.1371/JOURNAL.PONE.0272257
   PubMed Web of Science ®Google Scholar
• Yaghi S, Boehme AK, Dibu J, et al. Treatment and outcome of thrombolysis-related hemorrhage a multicenter retrospective study. JAMA Neurol. 2015;72(12):1451–1457. doi: 10.1001/jamaneurol.2015.2371
   PubMed Web of Science ®Google Scholar
• Matosevic B, Knoflach M, Werner P, et al. Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis. Neurology. 2013;80(13):1216–1224. doi: 10.1212/WNL.0b013e3182897015
   PubMed Web of Science ®Google Scholar
• Hanna-Sawires RG, Groen JV, Klok FA, et al. Outcomes following pancreatic surgery using three different thromboprophylaxis regimens. Br J Surg. 2019;106(6):765–773. doi: 10.1002/bjs.11103
   PubMed Web of Science ®Google Scholar
• Harker LA, Kadatz RA. Mechanism of action of dipyridamole. Thromb Res Suppl. 1983;29(SUPPL. 1):39–46. doi: 10.1016/0049-3848(83)90356-0
   Google Scholar
• Diener HC, Cunha L, Forbes C, et al. European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143(1–2):1–13. doi: 10.1016/S0022-510X(96)00308-5
   PubMed Web of Science ®Google Scholar
• Ariesen MJ, Tangelder MD, Lawson JA, et al. Risk of major haemorrhage in patients after infrainguinal venous bypass surgery: therapeutic consequences? The Dutch BOA (bypass oral anticoagulants or aspirin) study. Eur J Vasc Endovascular Surg. 2005;30(2):154–159. doi: 10.1016/j.ejvs.2005.03.005
   PubMed Web of Science ®Google Scholar
• Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc. 2005;53(4):655–659. doi: 10.1111/j.1532-5415.2005.53215.x
   PubMed Web of Science ®Google Scholar
• White RH, McKittrick T, Takakuwa J, et al. Management and prognosis of life-threatening bleeding during warfarin therapy. Arch Intern Med. 1996;156(11):1197–1201. doi: 10.1001/archinte.1996.00440100095011
   PubMedGoogle Scholar
• White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for Deep-Venous Thrombosis. Am J Med. 1999;107(5):414–424. doi: 10.1016/S0002-9343(99)00267-3
   PubMed Web of Science ®Google Scholar
• Rubboli A, Milandri M, Castelvetri C, et al. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting - clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiol. 2005;104(2):101–106. doi: 10.1159/000086918
   PubMed Web of Science ®Google Scholar
• Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovascular Dis. 1999;9(4):215–217. doi: 10.1159/000015958
   PubMed Web of Science ®Google Scholar